艾滋病患者用绥美凯治疗的效果

It has been approved for marketing in China and is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). What is the effect of Suimeikai on AIDS patients?

The therapeutic effect of Suimeikai in treating AIDS:

Suimeikai (alias: Domitabalamid Tablets) has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Through Suimeike's effective treatment, the lifespans of AIDS patients and healthy people are getting closer and closer. Medication compliance and convenience of medication play an increasingly important role in further improving patients' quality of life.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. Comparing it with the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir) in patients who failed to treat first-line treatment, Suimeike (alias: Dolutea Balamib Tablets) has significantly fewer drug-resistant mutation sites than the other two drugs, making it less likely to develop drug resistance.

(Alias: Doptabalamid Tablets) is a new drug used to treat AIDS, bringing new hope to AIDS patients. AIDS is an infectious disease that can be transmitted through sexual contact, blood, and mother-to-child transmission. Currently, there is still a lack of effective drugs to cure HIV infection worldwide. It can only reduce the viral load to the maximum and lasting extent and improve the patient's quality of life.

Recommended related hot articles: /newsDetail/71943.html